INTRODUCTION
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is an endothelium-specific mitogen that is pivotal in physiological and pathological angiogenesis. VEGF biological activities include the stimulation of endothelial cell growth and migration, the enhancement of microvascular permeability in i o, the promotion of vasculogenesis and angiogenesis and the induction of embryonic stem cell differentiation into haemopoietic precursors [1] .
The human VEGF gene is approx. 14 kb long, containing eight exons that give rise to a full-length mature polypeptide of 206 residues. Isoforms of 121, 145, 165 and 189 residues exist owing to alternative splicing. Except for VEGF "%& , the mouse homologues are VEGF "#! , VEGF "'% and VEGF ")) . The common isoforms, VEGF "#"
and VEGF "'& , contain exons 1-5 and 8, and 1-5 and 7-8 respectively. VEGF "'& , a 45 kDa homodimeric, heparin-binding glycoprotein, is a secreted product, although a significant portion is cell-associated. VEGF "#" is weakly acidic and secreted. Both isoforms show a dose-dependent mitogenic effect on endothelial cells. However, the lack of heparin-binding in VEGF "#" leads to a significant loss of mitogenic activity in comparison with VEGF "'& [1] [2] [3] [4] . Mice expressing VEGF "#! but lacking VEGF "'% and VEGF ")) have impaired myocardial angiogenesis, which leads to ischaemic cardiomyopathy [5] .
Translation of the VEGF mRNA is assumed to be initiated at an AUG codon (AUG"!$*), which is 1039 nt from its major transcriptional start site [6, 7] . The flanking sequences ACC AUG A contain Kozak's consensus sequence A to yield VEGF and three N-terminal fragments. When CTG%** was mutated to CGC, the precursor and N-terminal fragments were barely detectable. Although the precursor form was predominant in VEGF "'& , both CUG%** and AUG"!$* forms were found in VEGF "#"
. VEGF precursor induced neither the proliferation of human umbilical vein endothelial cells nor the expression of angiopoietin 2, which can be induced by, and act with, VEGF to induce tumour angiogenesis. The precursor also adheres to the extracellular matrix (ECM), suggesting that it might be a storage form for generating active VEGF in the cell or ECM. Alternate CUG%** and AUG"!$* initiation and processing of the inactive precursor and its products might be important in regulating angiogenesis.
Key words : angiogenesis, proteolysis, translation initiation. a signal peptide. Cleavage of the 26 residues from the AUG"!$* product is assumed to yield mature VEGF, with alanine as the first residue.
An alternate transcriptional start site of VEGF is present 633 nt downstream of the major site [9] . An internal ribosome entry site (IRES), which allows a cap-independent mode of initiation, is approx. 300 nt upstream of AUG"!$*. This IRES (IRES A) contains at least two elements ; another IRES is between nt 91 and 483 (IRES B) [9] [10] [11] [12] .
An in-frame CUG codon at nt 499 (CUG%**) in the 5h VEGF untranslated region (UTR) [3] might also function as an initiator and could produce a larger form of VEGF with 180 residues in the N-terminus, extended from the Met of AUG"!$*. CUG%**-flanking sequences GCG CUG%** A are conserved in cow [7] , rat [13] and mouse [14] . The multiple putative transcriptional initiation sites in the 5h UTR indicate that tissues might produce multiple VEGF isoforms depending on their degree of differentiation or angiogenesis. We have been interested in determining whether the VEGF isoforms expressed in normal tissues are the same as those expressed in tumours, because the different isoforms seem to exhibit distinct biological properties. Understanding the expression of different VEGF isoforms might be important for distinguishing between angiogenesis that occurs during tissue development, vascular remodelling and tumour formation. In the present study we investigated the VEGF isoforms expressed in normal human fetal tissues and ovarian tumours. We found that ovarian tumours and some fetal tissues express a 47 kDa VEGF precursor protein, which arises predominantly from CUG%** initiation. The VEGF precursor, which can interact with the extracellular matrix (ECM), also undergoes proteolysis at two sites to produce VEGF and 10, 22 and 28 kDa N-terminal fragments. These studies suggest that the precursor is processed into active VEGF isoforms, which participate in angiogenesis in tumour tissues.
EXPERIMENTAL

DNA constructs
All PCR was done with Pfu DNA polymerase (Stratagene, La Jolla, CA, U.S.A.), and all cDNA species were sequenced in their entirety on both strands of DNA with standard vector primers and internal primers with an ABI automated sequencer at the University of California, San Francisco (UCSF) Biomolecular Resource Center (San Francisco, CA, U.S.A.).
To clone full-length VEGF "#" and VEGF "'& cDNA species, cytoplasmic RNA of the SKOV3 ovarian cancer cell line was reverse-transcribed with random primers and amplified with primers 5h-TATTATAAGCTTTCGCGGAGGCTTGGGGCA-G-3h (sense) and 5h-GATATACTCGAGTCTAGATCACCGC-CTCGGCTTGTCACA-3h (anti-sense). The PCR products were cloned into pCMV vector. Sequences of the full-length VEGF cDNA species agreed with the published sequence [3] . To delete the first 956 nt of the 5h UTR in 165 ∆956, VEGF "'& cDNA was digested with NarI\HindIII and Klenow-treated with all four dNTPs (50 µM) ; the linearized plasmid DNA was then religated.
Site-directed mutagenesis was performed with the QuikChange Site-Directed Mutagenesis kit (Stratagene). Full-length mutant CUG (mCUG) has codon CGC (Arg) replacing CTG%** (Leu"); this was done with VEGF "#"
and VEGF "'& wild-type (wt) templates by using primers 5h-CTGACCAGTCGCGCGCAC-GGACAGAC-3h (sense) and 5h-GTCTGTCCGTGCGCGCG-ACTGGTCAG-3h (anti-sense). Mutation of ATG"!$* to GTC (Val) in mutant AUG (mAUG) was done with primers 5h-CGGGCCTCCGAAACCGTCAACTTTCTGCTG-3h (sense) and 5h-CAGCAGAAAGTTGACGGTTTCGGAGGCCCG-3h (anti-sense). BssHII and HincII sites respectively were created by these mutations, facilitating the screening of bacterial colonies. Double mutants of CUG%** and AUG"!$* were made by ligating a 588 nt HindIII-SacII fragment from the mCUG plasmid to HindIII\SacII-digested mAUG vectors.
To make constructs F-Sac, which had the Asp-Tyr-Lys-AspAsp-Asp-Asp-Lys (FLAG) tag via site SacII, between Arg$! and Gly$" in VEGF precursor, VEGF cDNA species were digested with SacII, Klenow-treated with 50 µM dGTP and ligated to preannealed oligonucleotides 5h-CCGCGACTACAAGGACG-ACGACGACAAG-3h (sense) and 5h-CCCCTTGTCGTCGTC-GTCCTTGTAGTCGC-3h (anti-sense). Constructs F-Nar had the FLAG tag via site NarI, between Gly"&$ and Ala"&%, and were made by digesting VEGF cDNA species with NarI, Klenow treatment with dCTP and ligation to preannealed oligonucleotides 5h-GAGGCGGATCCGACTACAAGGACGACG-ACGACAAGCG-3h (sense) and 5h-GGCGCGCTTGTCGTCG-TCGTCCTTGTAGTCGGATC-3h (anti-sense). To make constructs F-Mut, in which 10 residues in proteolytic site 1 were replaced by the FLAG epitope, PCR was performed with primers 5h-CATTATAAGCTTTCGCGGAGGCTTGGGGCAG-3h (sense) and 5h-GTCCTTGTAGTCGACGTAGAGCAGCAA-GGCGAG-3h (anti-sense). The PCR product was Klenowtreated with dGTP and digested with HindIII. PCR also was performed with primers 5h-ACGACGATGACAAGCTTCCC-ATGGCAGAAGGAGGA-3h (sense) and 5h-GATATACTCG-AGTCTAGATCACCGCCTCGGCTTGTCACA-3h
(antisense) ; the PCR product was Klenow-treated in dCTP and digested with XbaI. Both PCR products were cloned into pCMV vector. Constructs F-Sac-Mut had the SacII FLAG tag plus the 10-residue mutation\tag of proteolytic site 1 ; they were made by removing a 695 nt NheI fragment from the F-Mut plasmids and ligation of a 695 nt NheI fragment from the F-Sac plasmids.
To delete the first 475 nt (BamHI) and 485 nt (P uII) of the 5h UTR, F-Sac-Mut plasmids were digested with BamHI and with P uII\XbaI respectively. The BamHI-digested plasmids were Klenow-treated, digested with XbaI and cloned into pCMV vector (digested with HindIII, Klenow-treated and digested with XbaI). To delete sequences between sites SacII and SmaI (nt 588 and 919), F-Mut plasmids were digested with SacII, Klenowtreated and digested with XbaI. These vectors were ligated to SmaI\XbaI fragments from F-Mut plasmids. To delete sequences between sites XmnI and SmaI (nt 658 and 919), F-Sac-Mut plasmids were digested with HindIII and XmnI, and with SmaI and XbaI, to yield respectively 663 nt, and 564 and 696 nt fragments, and cloned into pCMV vector.
The DNA sequence encoding proteolytic site 2 is upstream of site NarI. Thus, to make construct N-terminal-22k, which produced a product analogous to the 22 kDa N-terminal fragment, VEGF "'& cDNA was digested with NarI\XbaI. A TAG stop codon was introduced downstream of site NarI by ligating the digested plasmid to preannealed oligonucleotides 5h-CGCT-AGGCCGAGGAGAGCGGGCGG-3h (sense) and 5h-CTAGC-GGCCCGCTCTCCTCGGCCTAG-3h (anti-sense).
Tissue samples
Human fetal tissues were obtained from second-trimester pregnancies (16-23 weeks) after elective termination. 
Transfection
Transfection was done with the Effectene reagent (Qiagen, Valencia, CA, U.S.A.). To monitor transfection efficiency, a pGL3-luc control plasmid was included in each transfection. Transfection time was 24-48 h depending on cell type. Before being harvested, cells were incubated in conditioned medium (CM) for 24 h.
Cell proliferation assay
Subconfluent HUVEC (six-well plates, passage 4-5) were transfected with 165 ∆956 and 165 F-Sac-Mut mAUG, grown for 48 h, trypsinized, replated at lower densities and grown for a further 48 h. The cell proliferation assay was performed in triplicate from three separate transfection experiments with a Celltiter 96 aqueous one-solution cell proliferation assay from Promega (Madison, WI, U.S.A.). D %*! data were normalized to transfection efficiency.
Monolayer and ECM preparation
Cells were incubated with 125 mM NaCl\5 mM KCl\50 mM Hepps (pH 7)\5 mM glucose\1 mM EDTA (pH 8) at 37 mC for 10 min and washed twice in the same buffer [15] . The monolayer was collected and pelleted, then lysed in the presence of protease inhibitors. The ECM portion was washed with PBS, pelleted and lysed. The ECM protein content was 2 % of the cell monolayers, as determined with the protein assay kit (Bio-Rad, Hercules, CA, U.S.A.).
Western blotting
For Western blotting, proteins were transferred to a PVDF membrane (Millipore, Bedford, MA, U.S.A.). The antibodies used were against human VEGF (Upstate Biotech, Lake Placid, NY, U.S.A.), M2 FLAG (Sigma, St Louis, MO, U.S.A.), vascular endothelial cadherin (VE-cadherin ; Research Diagnostics, Flanders, NJ, U.S.A.), angiopoietin 2 (Ang2 ; a gift from Dr G. D. Yancopoulos, Regeneron, Tarrytown, NY, U.S.A.) and the unique 180 N-terminal residues (described below). An ECL2 Plus enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, U.S.A.) was used.
N-terminal antibody
To express the 180-residue N-terminal fragment in Escherichia coli, PCR was performed with primers 5h-AAAGGATCCCT-GACGGACAGACAGACAGAC-3h (sense) and 5h-AAAGAA-TTCGGTTTCGGAGGCCCGACC-3h (anti-sense). The PCR product was cloned into pET-21a vector (Novagen, Madison, WI, U.S.A.). Purification of the 180-residue peptide with the Hisbind resin was done as recommended by the manufacturer. The polyclonal antibody was produced in rabbits by using the BabCO (Richmond, CA, U.S.A.) custom antibody service. The specificity of the T7N4 antibody was tested with the purified N-terminal peptide.
RESULTS
Endogenous expression of a 47 kDa VEGF form
We initially sought to determine VEGF expression in ovarian tumours and fetal tissues using Western blotting with anti-VEGF antibody. We observed 15, 18 and 23 kDa bands ( Figure  1A , lanes 1-6, 10 and 11), corresponding to the sizes of VEGF "#" and VEGF "'& respectively [2] . Unexpectedly, all ovarian tumours ( Figure 1A , lanes 2-4) and most of the fetal tissues studied (lanes 5 and 8-11) produced a 47 kDa band, which could have been a large VEGF form with a 180-residue N-terminal extension, initiated from CUG%**. The 30 kDa band in Figure 1 (A), lanes 1-7 and 9-11, could have been non-specific because we also observed this pattern in the transfection experiments described below. To explore the expression and role of the 47 kDa band, we raised T7N4 antibody against the 180 N-terminal residues ( Figure 1B ) and analysed a fetal ovary and four ovarian tumours by Western blotting. The 47 kDa band previously detected with anti-VEGF antibody was detected in the same ovarian tumours with antibody T7N4 ( Figure 1C ). Because the CUG%** product contained proteolytic site 1, this cleavage alone was likely to yield VEGF and an N-terminal fragment ( Figure 1B) . However, antibody T7N4 also recognized 28 and 22 kDa bands ( Figure  1C ), which were probably N-terminal fragments arising from proteolysis of the precursor.
Product from CUG
, the predominant upstream initiator, undergoes proteolysis
To determine whether the 47 kDa band originated from CUG%** initiation, full-length cDNA species were tagged with FLAG ; mutations of CTG%** to CGC and ATG "!$* to GTC were introduced into a subset of these constructs (Figure 2A) . Whereas the mutational analysis permitted the evaluation of whether CUG%** was used for initiation, the introduction of tags at sites SacII and NarI permitted the detection of this initiation product and also a determination of the origins of the 28 and 22 kDa fragments seen in Figure 1(C) . After transfection into COS1 precursor. P1 and P2 denote cleavage sites 1 and 2 (downwards-pointing arrows) respectively. Cleavage at P1 yields VEGF and the 28 kDa N-terminal fragment. Subsequent cleavage at P2, N-terminal to the Nar I tag, could yield the 22 and 10 kDa N-terminal fragments, which probably span the N-terminus and C-terminus respectively of the 28 kDa N-terminal fragment. The exact location of site 2 was not determined. The positions of molecular mass markers are indicated (in kDa) at the left in (B) and (C). cells, the Western blot was probed with anti-FLAG antibody under reducing conditions. Bands of 42 or 47 kDa were seen when CUG%** was intact in VEGF "#"
and VEGF "'& respectively ( Figure 2B, lanes 1, 3, 5, 7 and 8) . However, when CTG%** was mutated ( Figure 2B, lanes 2, 4 and 6 ), the intensities of these bands were decreased, indicating that the 42 and 47 kDa bands were predominantly CUG%** products. Additional bands of 22 and 28 kDa ( Figure 2B, lanes 1, 3, 5 and 7 ) and 10 and 28 kDa (lane 8) respectively were detected. The 10, 22 and 28 kDa fragments were probably proteolytic products of the 42\47 kDa precursor forms, which was consistent with the data in Figure 1(C) .
Although the 42, 47, 28, 22 and 10 kDa bands were predominantly cell-associated, only the 22 and 47 kDa bands could be detected in CM ( Figure 2B, lane 7) . When analysed under non-reducing conditions, there was little change in the apparent molecular mass of the 10, 22 and 28 kDa bands, indicating that these proteins were predominantly monomers (results not shown).
When probed with anti-VEGF antibody ( Figure 2C ), 15\18 and 21\23 kDa bands were present in VEGF "#"
and VEGF "'& cDNA species respectively. In 121 F-Sac mAUG and 165 F-Sac mAUG ( Figure 2C, lanes 1 and 5) , the VEGF forms were likely to arise from proteolysis of the precursor proteins rather than from the AUG"!$* product.
As summarized in Figure 2 (D), the VEGF precursor was probably processed at two sites, P1 and P2, to yield VEGF and 10, 22 and 28 kDa N-terminal fragments.
Predominant form of VEGF 165 is the 47 kDa precursor
Because VEGF could arise by cleavage at site 1 in both CUG%** and AUG"!$* products, this hampered the evaluation of the relative strengths of CUG%** and AUG"!$*. To overcome this difficulty, proteolytic site 1 was mutated by replacing residues 198-207 of the signal peptide in the precursor with FLAG ( Figure 3A) . Only the C-core in the signal peptide was altered by this mutation. In this experiment, AUG"!$* proteins had an additional uncleaved 26 residues at the N-terminus and were expected to migrate to a point corresponding to 3.3 kDa larger After transfection into COS1 cells, Western blots were probed with the anti-FLAG and anti-VEGF antibodies. In VEGF "'& the predominant band was the 47 kDa precursor ( Figure 3B, lanes 1  and 2) . However, 121 F-Sac-Mut wt gave 42 and 18\22 kDa bands ( Figure 3B, lane 3) , corresponding to the sizes of the precursor and AUG"!$* forms of VEGF "#" respectively. Although constructs 121 and 165 F-Sac-Mut mAUG carried mutations of proteolytic site 1 and GTC "!$* instead of ATG, processing at site 2 alone might still have occurred in the precursor to yield the 22 kDa N-terminal fragment. This proteolytic product could be detected by anti-FLAG antibody but not by anti-VEGF antibody. However, when probed with the former, constructs 121 and 165 F-Sac-Mut mAUG produced 
Figure 6 VEGF precursor is detected in the ECM preparation
Western blot of cell monolayer and ECM fractionated from one plate of COS1 cells transfected with 121 F-Sac-Mut wt, probed with the anti-FLAG antibody under reducing conditions. The 18/22 kDa AUG 1039 form of VEGF 121 is the positive and negative control respectively in cell monolayer and ECM [15] . The positions of molecular mass markers are indicated (in kDa) at the left.
the unprocessed precursors ( Figure 3B, lanes 2 and 4) , suggesting that processing at site 2 was inefficient when site 1 was mutated.
To examine whether the results above were cell-specific, we conducted a similar experiment in the ovarian cancer cell line OVCAR3 ( Figure 3C ). When probed with anti-FLAG antibody, the 47 kDa ( Figure 3C , lane 1) and 42 kDa (lanes 3 and 4) bands were detected above the background. Construct 121 F-Sac-Mut wt also gave the 18\22 kDa AUG"!$* form of VEGF "#"
( Figure  3C , lane 2), which is consistent with the results for COS cells.
CUG 499 recognition in VEGF 121 and VEGF 165 is influenced by downstream sequences
CUG%** is suboptimal as it lacks the favourable A −$ and G +% . To determine whether CUG%** recognition is influenced by cisacting element(s), we made 5h UTR deletions ( Figure 4A ).
After transfection into COS1 cells, the derived Western blot was analysed with anti-FLAG antibody. CUG%** initiation was The Western blots of cell lysates were probed under reducing conditions with antibodies against VE-cadherin (C), an endothelium-specific adhesion protein [27, 28] , and Ang2 (D). The 75 and 64 kDa bands correspond to the sizes of glycosylated and non-glycosylated Ang2 respectively [29] . The positions of molecular mass markers are indicated (in kDa) at the left in (A) and (C).
apparently unaffected despite the removal of 485 nt of the 5h UTR in VEGF "#"
and VEGF "'& ( Figure 4B , lanes 4 and 6). To determine whether CUG%** initiation was influenced by downstream sequences, two internal deletions were made of nt 658-919 (∆658-919) and 588-919 (∆588-919), corresponding to residues 54-140 and 30-140 respectively. In these deletions, the precursors were predicted to be 26 and 29 kDa for VEGF "#" and 30 and 33 kDa for VEGF "'& respectively. The truncated CUG%** precursor in 165 F-Sac-Mut ∆658-919 wt produced a 36 kDa band ( Figure 4C, lane 7) that was absent when CTG%** was mutated (lane 8) and also from the deletion ∆588-919 (lanes 13 and 14) . However, CUG%** product was not detected in deletions ∆588-919 and ∆658-919 of VEGF "#"
( Figure 4C, lanes 9-12) . Both deletions ∆658-919 and ∆588-919 yielded the 18\22 kDa ( Figure 4C , lanes 9 and 11) and 25 kDa (lanes 8 and 13) bands, corresponding to the sizes of the AUG"!$* products of VEGF "#"
and VEGF "'& respectively.
VEGF precursor yields predominantly monomers
The dimerization of VEGF is essential for biological activity and occurs via disulphide bonds [16] . VEGF "'& precursor could also form dimers because it has 18 cysteine residues, two of which are at positions 61 and 126 in the N-terminal region. When analysed by Western blotting with the anti-FLAG antibody, the VEGF "'& precursor and the AUG"!$* forms of VEGF "#"
and VEGF "'& migrated at 47, 46 and 40 kDa respectively under non-reducing conditions ( Figure 5 ).
VEGF precursor is associated with the ECM
Although the VEGF precursor was detected in the CM ( Figure  2B ), a significant portion was cell-associated. To determine whether the latter was associated in part with the ECM, COS1 cells were transfected with 121 F-Sac-Mut wt, containing a mutation of proteolytic site 1 and producing the VEGF "#" 42 kDa precursor and the 18\22 kDa AUG"!$* form. Fractionated cell monolayer and ECM were probed with the anti-FLAG antibody.
Previously, VEGF "#" derived presumably from the AUG"!$* product was detected in cell monolayers but not in the ECM [15] . In the present study, the 18\22 kDa AUG"!$* form of VEGF "#" was also detected only in cell monolayers ( Figure 6 ). The 42 kDa precursor was detected in both cell monolayers and ECM. Even though the protein content of cell monolayers loaded on the gel was 50-fold that of the ECM, the level of the 42 kDa precursor in cell monolayers was 8-fold that in the ECM. Thus a substantial portion of the precursor was likely to be associated with the ECM. Translation and processing of vascular endothelial growth factor precursor
Biological significance of VEGF 165 precursor
Secreted VEGF can induce the proliferation of endothelial cells such as HUVEC. The VEGF precursor is detectable in CM and might also function as a mitogen. Therefore 165 ∆956 and F-SacMut mAUG, which produced VEGF "'& and the unprocessed VEGF "'& precursor respectively, were transfected into HUVEC ( Figure 7A ). The former construct was the positive control because it was expected to secrete bioactive VEGF "'& . Construct 165 ∆956 induced HUVEC proliferation 2-fold but 165 F-SacMut mAUG did not ( Figure 7B ).
During tumour angiogenic induction, Ang2 can act cooperatively with VEGF [17] . As Ang2 protein synthesis can also be induced by VEGF in bovine retinal endothelial cells [18] , we sought to determine whether the VEGF "'& precursor acted similarly. HUVEC were transfected with the constructs above and with a new construct, N-terminal-22k, which yielded a product analogous to the 22 kDa N-terminal fragment. After transfection, cell lysates were probed with VE-cadherin and Ang2 antibodies. Although the levels of VE-cadherin were comparable ( Figure 7C ), the Ang2 level increased 2.5-fold when HUVEC were transfected with construct 165 ∆956, compared with 165 F-Sac-Mut mAUG and N-terminal-22k ( Figure 7D ).
DISCUSSION
Here we have identified a new VEGF precursor expressed in human ovarian tumours and some fetal tissues. Our studies demonstrate that the precursor undergoes proteolysis at two sites to yield VEGF isoforms and 10, 22 and 28 kDa N-terminal fragments (Figure 8) .
Although IRES B (nt 91-483 [10] ) could potentially promote initiation from the suboptimal CUG%**, this IRES might have little influence under normal conditions. Instead, CUG%** recognition could be controlled by at least two separate, overlapping, downstream regions in VEGF "#"
and VEGF "'& . As predicted by the RNAStructure 3.5 program [19] , when exon 7 is present, the 72 % GC-rich 70 nt region (nt 588-658) could form a specific downstream secondary structure in VEGF "'& (results not shown). This could slow ribosome scanning, enhancing CUG%** rec- ognition. In VEGF "#"
, CUG%** recognition is influenced by sequences from nt 588 to 919, which contains IRES A (nt 745-1038), predicted to base-pair extensively [9, 10] . Thus in VEGF "#"
, IRES A might have a dual function in aiding CUG%** recognition via the formation of secondary structure and facilitating AUG"!$* initiation without scanning.
AUG"!$* initiation could also be controlled in a sequencespecific manner in VEGF "#"
and VEGF "'& . Domains D1-D3 (nt 845-938) in IRES A are predicted to form a Y-shaped secondary structure common to IRES elements [9] . Analysis with the RNAStructure 3.5 program [19] revealed the Y-shaped structure upstream of AUG"!$* in VEGF "#"
(results not shown) ; however, the integrity of the IRES A Y-shaped structure is altered and not evident in a similar analysis of VEGF "'& . This is consistent with the role of IRES A in stimulating AUG"!$* initiation in VEGF "#" but not in VEGF "'& . Our results (Figure 2) showed that the precursor and mature products were present at lower intensities when CUG%** and AUG"!$* were mutated. Further, we have found that VEGF "#" and VEGF "'& were still produced when the first 588 nt of the 5h UTR were deleted in mutant AUG constructs, ∆588 mAUG (results not shown) but not in ∆694 mAUG, which lacked the first 694 nt of the 5h UTR. Because CUG%** is preceded by an inframe UGA%)( stop codon, the results suggest that one or more initiation codon(s) lies between CUG%** and nt 694. Initiations from codons ACG and GUG occur with an efficiency 2.5-5-fold lower than that from CUG [20] . Although CUG%** and AUG"!$* are the predominant initiation codons in VEGF, it is possible that ACG&!#, GUG&') and CUG'&# might also be used for initiation to yield precursors 1, 23 and 51 residues smaller than that of CUG%**. However, judging by the weak intensities of bands from the double-mutant construct in Figure 2 , initiations from ACG&!#, GUG&') and CUG'&# might occur at lower efficiencies.
We confirmed that cleavage at site 1 occurs in the 26-residue signal sequence in the middle portion of the precursor. As predicted with the SignalP-NN and SignalP-HMM programs [21] , an N-terminal signal sequence could be present in the precursor between residues 46-67, with low probabilities of cleavage between Ala'( and Val'). The predicted product from this cleavage is an 8 kDa N-terminal fragment detectable in construct F-Sac, because it contains the FLAG tag. However, the predominant bands found were 22 and 28 kDa, indicating that cleavage did not occur between Ala'( and Val').
Previous studies have shown that members of the plateletderived growth factor (PDGF)\VEGF family, including PDGF-AA, VEGF-C and VEGF-D, are synthesized as precursors that undergo proteolysis [22] [23] [24] . Alignment of PDGF-AA and VEGF precursor sequences (using the MegAlign Program ; results not shown) showed similarity between the PDGF-AA proteolytic site (i.e. KRSIEE ; single-letter amino acid codes) and those predicted for site 2 in the VEGF precursor (RRGAEE). A similar analysis showed similarity between the intracellular cleavage site in the VEGF-C precursor (i.e. RRSLPA) and the VEGF proteolytic site 1 (KWSQAA). Both cleavages yield the bioactive VEGF and VEGF-C, suggesting that both precursors might be processed by similar protease(s). Thus precursor synthesis and proteolysis might be evolutionarily conserved in the PDGF\VEGF family and might be important in regulating angiogenesis.
We have found that VEGF expression is greatest in tissues known to undergo active angiogenesis (i.e. ovarian tumours, placenta, and fetal ovary, heart, lung and spleen) [25, 26] . The high levels of VEGF in these tissues probably originate from the processing of both CUG%** and AUG"!$* products. Processing of CUG%**-derived precursors might be a major source for active VEGF products that mediate angiogenesis in ovarian tumours and some fetal tissues.
In summary, we have identified a new VEGF precursor expressed in ovarian tumours and some fetal tissues, and have shown that, unlike VEGF, the precursor interacts with the ECM. The VEGF precursor is inactive in stimulating HUVEC proliferation and Ang2 production, suggesting that it might function as a storage form that can be processed into active VEGF isoforms in either the cell or ECM.
